Alpha-PET for Prostate Cancer: Preclinical investigation using ¹⁴⁹Tb-PSMA-617.

ABSTRACT: In this study, it was aimed to investigate ¹⁴⁹Tb-PSMA-617 for targeted α-therapy (TAT) using a mouse model of prostate-specific membrane antigen (PSMA)-expressing prostate cancer. ¹⁴⁹Tb-PSMA-617 was prepared with >98% radiochemical purity (6 MBq/nmol) for the treatment of mice with PSMA-positive PC-3 PIP tumors. ¹⁴⁹Tb-PSMA-617 was applied at 1 × 6 MBq (Day 0) or 2 × 3 MBq (Day 0 & Day 1 or Day 0 & Day 3) and the mice were monitored over time until they had reached a pre-defined endpoint which required euthanasia. The tumor growth was significantly delayed in mice of the treated groups as compared to untreated controls (p < 0.05). TAT was most effective in mice injected with 2 × 3 MBq (Day 0 & 1) resulting in a median lifetime of 36 days, whereas in untreate

SUBMITTER: Umbricht CA 

PROVIDER: S-EPMC6882876 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature